SCHEMBL299272

SCHEMBL299272

CS(=O)(=O)c1cccc(-c2cnc3[nH]cc(C(=O)c4cccc(N)c4)c3c2)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CAMKK2 Q96RR4 2/20 0.61
AAK1 Q2M2I8 1/20 0.52
KIT P10721 5/20 0.49
NTRK1 P04629 4/20 0.47
AXL P30530 3/20 0.47
PLK4 O00444 3/20 0.47
PIK3CA P42336 3/20 0.47
DYRK1A Q13627 2/20 0.47
CDC7 O00311 1/20 0.47
CHEK1 O14757 1/20 0.47
AURKA O14965 1/20 0.47
MAPK13 O15264 1/20 0.47
PDPK1 O15530 1/20 0.47
DYRK3 O43781 1/20 0.47
ROCK2 O75116 1/20 0.47
RPS6KA5 O75582 1/20 0.47
PRKD3 O94806 1/20 0.47
PAK4 O96013 1/20 0.47
CHEK2 O96017 1/20 0.47
ABL1 P00519 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3702374 0.90 CAMKK2 (0.69) CAMKK2AAK1NTRK1AXLPLK4
SCHEMBL4570626 0.89 CAMKK2 (0.61) CAMKK2AAK1NTRK1AXLPLK4
SCHEMBL298800 0.87 TNIK (0.54) CAMKK2AAK1KITNTRK1PIK3CA
SCHEMBL298899 0.86 CAMKK2 (0.56) CAMKK2KITAXLPLK4RIPK1
SCHEMBL858632 0.86 NTRK1 (0.64) CAMKK2AAK1KITNTRK1AXL
SCHEMBL856998 0.83 KIT (0.57) AAK1KITNTRK1AXLPLK4
SCHEMBL3699186 0.82 NTRK1 (0.64) AAK1KITNTRK1AXLPLK4
SCHEMBL7872452 0.82 AAK1 (0.51) AAK1KITNTRK1AXLPLK4
SCHEMBL298592 0.81 CAMKK2 (0.52) CAMKK2AAK1KITNTRK1PLK4
SCHEMBL858562 0.81 KIT (0.66) AAK1KITNTRK1AXLPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 US disclosed
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 US disclosed
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 US disclosed
EP-2427433-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS Plexxikon, Inc. (US) 2012-03-14 EP disclosed
WO-2010129570-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. (US) 2010-11-11 WO disclosed
WO-2010129570-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. (US) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS BRAF, RAF1, ARAF CAMKK2 497/4885AAK1 247/4885KIT 1330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.